You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
泰格醫藥(03347.HK)年度經調整淨利增長60.6%至15.85億元

格隆匯3月28日丨泰格醫藥(03347.HK)發佈公吿,截至2021年12月31日止年度,實現收入人民幣52.135億元,同比增長63.3%;毛利22.481億元,同比增長49.5%;公司擁有人應占淨利潤28.791億元,同比增長64.4%;公司擁有人應占經調整淨利潤15.853億元,同比增長60.6%;基本每股盈利3.32元;擬派末期股息每10股人民幣5元(含税)。

回顧2021年,集團延續服務客户的強勁勢頭,將關鍵創新產品推向市場,從實驗室服務到臨牀試驗,從項目啟動到交付,從孤兒藥到疫苗,集團對於在取得成就的同時為患者、客户、專業人士、社區、股東等利益相關者創造價值而感到自豪。報吿期間,集團的收入同比增長63.3%。臨牀試驗技術服務產生的收入達人民幣29.937億元,而臨牀試驗相關服務及實驗室服務產生的收入達人民幣22.198億元,分別同比增長97.1%及32.7%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account